Home LiteratureArticle Details
PMID: 6205091 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 133 ·No. 3 ·1984-09-00 ·Pages 1671-6

Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T

Abstract

The present study determines the Ly phenotype of T cells mediating tumor cell rejection in vivo and investigates some of cellular mechanisms involved in the in vivo protective immunity. C3H/HeN mice were immunized to syngeneic X5563 plasmacytoma by intradermal (i.d.) inoculation of viable X5563 tumor cells, followed by the surgical resection of the tumor. Spleen cells from these immune mice were fractionated by treatment with anti-Lyt antibodies plus complement, and each Lyt subpopulation was tested for the reconstituting potential of in vivo protective immunity in syngeneic T cell-depleted mice (B cell mice). When C3H/HeN B cell mice were adoptively transferred with Lyt-1-2+ T cells from the above tumor-immunized mice, these B cell mice exhibited an appreciable cytotoxic T lymphocyte (CTL) response to the X5563 tumor, whereas they failed to resist the i.d. challenge of X5563 tumor cells. In contrast, the adoptive transfer of Lyt-1+2- anti-X5563 immune T cells into B cell mice produced complete protection against the subsequent tumor cell challenge. Although no CTL or antibody response against X5563 tumors was detected in the above tumor-resistant B cell mice, these mice were able to retain Lyt-1+2- T cell-mediated delayed-type hypersensitivity (DTH) responses to the X5563 tumor. These results indicate that Lyt-1+2- T cells depleted of the Lyt-2+ T cell subpopulation containing CTL or CTL precursors are effective in in vivo protective immunity, and that these Lyt-1+2- T cells implement their in vivo anti-tumor activity without inducing CTL or antibody responses. The mechanism(s) by which Lyt-1+2- T cells function in vivo for the implementation of tumor-specific immunity is discussed in the context of DTH responses to the tumor-associated antigens and its related Lyt-1+2- T cell-mediated lymphokine production.

MeSH Terms
Animals Antigens, Ly/immunology Antigens, Neoplasm/immunology Cytotoxicity, Immunologic Epitopes Histocompatibility Antigens/immunology Immunization, Passive Lymphocyte Cooperation Lymphocyte Depletion Mice Mice, Inbred C3H Phenotype Plasmacytoma/immunology,therapy Stem Cells/immunology T-Lymphocytes/immunology,transplantation T-Lymphocytes, Cytotoxic/immunology,transplantation
Chemicals
Antigens, Ly Antigens, Neoplasm Epitopes Histocompatibility Antigens tumor-associated transplantation antigen
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Fujiwara H
Fukuzawa M
Yoshioka T
Nakajima H
Hamaoka T
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
1984-09-00
Pages
1671-6
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]